Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

NCT01337505 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Solid Tumour

Interventions

DRUG: INNO-206

Sponsor

ImmunityBio, Inc.